Hi all AVRers, do hope my posting come out OK--
I believe a word in the heading did not impress some and some were expecting a bigger 'fanfare' on results
Would love someone to answer my Question at foot.
The word ' interim ' - --'the intervening time'. --'In the interim' -- 'I'll just keep my fingers crossed'
I believe if that word was excluded then maybe a better result, even with market a bit jittery. Remember the world will not end. Life will go on!!!!
Having said that I believe the report is fantastic- considering :-
-the age of the patients 'mean age 73'
-their results- I get the impression some are now in better shape than before the implant ???.
-the Doctors cannot be too expressive with their words, even though some descriptions were
extremely positive like the following :-
(you must read the report fully as I have been bias and ' picked ' out what I like)
--average 86% improvement in mean gradient (standard measure of stenosisseverity) from pre-treatment levels.
--mean gradients were up to 50% lower than other TAVR devices
--all patients are in the normal or near normal range compared to the general population with normal valve function.
--average Effective Orifice Area (EOA) up to 45% larger than those reported with other TAVR devices in matched annular sizes.2
--no conduction (heart rhythm) disturbances due to the procedure -
--no clinically significant paravalvular regurgitation despite very complex and heavily calcified anatomy.
--echocardiographic and CT imaging data showed consistent laminar flow throughout valve
--long coaptation length in all five patients. Ostensibly, indicate lower leaflet strain leading to long term durability.
--allowed for excellent commissural alignment; a significant patient benefit if future coronary intervention were required.
--making available a TAVRthat works better from the get-go and lasts longer,
-- 20% increase from baseline in 6 min walk test (a measure of patient exercise tolerance)- a 170% greater improvement
than observed in studies of other TAVR valves --a marked improvement in patients’ functional status and exercise tolerance.
--exercise performance is a critical marker of cardiac health.
--Dr. Paul Sorajja, -at Abbott Northwestern Hospital (see comment below) one of the implanting physicians “Due to its unique
leaflet design,DurAVR™continues to provide superior haemodynamics with a balloon expandable platform”.
--Dr. Vinnie Bapat, -- another member of the team - stated, “DurAVR™ rationally engineered to provide ease of implantation for the doctor,
immediate haemodynamic benefit for the patient post-implantation, potential to provide a long-term durable effect. of utmost importance
when treating younger, low-risk patients.
-- are happy to see patients on this trial doing so well with such impressive haemodynamic improvement
--"DurAVRTM continues to exceed very high expectations in a complex group of bicuspid and tricuspid patients.
The haemodynamic performance as well as valve function is remarkable.
--patients’functional status improved as did their exercise performance indicating early improvements in quality-of-life due to receiving DurAVR™
--Wayne's comments -some not all
-- '-- mimics a native aortic valve'
-- exercise performance is incredibly important and supports the use of DurAVR™ in this more active patient group who require a valve that lasts
longer and works better than current solutions.
-- represents a small No. of patients and should be viewed as such
--more results during2022,”
QUESTION - Abbott Northwestern Hospital-Remember Abbott (the one I have read about) is a big $US 230b appx Coy and from my research (read about it some time ago) is/ could be very interested in AVR's product. It is in the health industry.
I wonder is there any connection ( site map then look in -vascular-) https://www.aus.abbott/site-map.html
(20min delay)